The Effectiveness of Local Consolidative Therapy for Advanced Lung Adenocarcinoma Harboring EGFR Mutation Treated With First-line Afatinib

被引：0
|
作者：
Tsai, Y. [1 ]
Tsai, M. [2 ]
Ma, J. [2 ]
Kuo, C. [2 ]
Yang, C. [2 ]
Wu, K. [2 ]
Lee, M. [2 ]
Lee, Y. [3 ]
Huang, C. [4 ]
Hung, J. [1 ]
Chong, I. [2 ]
机构：
[1] Kaohsiung Med Univ, Kaohsiung Municipal Ta Tung Hosp, Div Pulm & Crit Care Med, Kaohsiung, Taiwan
[2] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Div Pulm & Crit Care Med, Kaohsiung, Taiwan
[3] Kaohsiung Med Univ, Kaohsiung Municipal Ta Tung Hosp, Dept Surg, Kaohsiung, Taiwan
[4] Kaohsiung Med Univ, Kaohsiung Municipal Ta Tung Hosp, Dept Radiat Oncol, Kaohsiung, Taiwan
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2023年 / 207卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A2728
引用
收藏
页数：1
相关论文
共 50 条
  • [21] First-Line Management of EGFR-Mutated Advanced Lung Adenocarcinoma: Recent Developments
    Bin-Chi Liao
    Chia-Chi Lin
    James Chih-Hsin Yang
    Drugs, 2013, 73 : 357 - 369
  • [22] First-Line Management of EGFR-Mutated Advanced Lung Adenocarcinoma: Recent Developments
    Liao, Bin-Chi
    Lin, Chia-Chi
    Yang, James Chih-Hsin
    DRUGS, 2013, 73 (04) : 357 - 369
  • [23] Gefitinib versus erlotinib as first-line treatment in EGFR mutant advanced lung adenocarcinoma
    Shee, Chai Chee
    Kin, Liam Chong
    Kek, Pang Yong
    Siong, Kow Keng
    Ern, Poh Mau
    Kuan, Wong Chee
    Liang, Tan Jiunn
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [24] Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation
    Urban, Laszlo
    Doczi, Robert
    Vodicska, Barbara
    Tihanyi, Dora
    Horvath, Magdolna
    Kormos, Dora
    Takacs, Istvan
    Papai-Szekely, Zsolt
    Poka-Farkas, Zsuzsanna
    Varkondi, Edit
    Schwab, Richard
    Hegedus, Csilla
    Valyi-Nagy, Istvan
    Petak, Istvan
    CLINICAL LUNG CANCER, 2021, 22 (01) : E112 - E115
  • [25] The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation
    Wu, Shang-Gin
    Yu, Chong-Jen
    Yang, James Chih-Hsin
    Shih, Jin-Yuan
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [26] Randomized phase II study of erlotinib as first-line or second-line therapy for EGFR mutation-positive advanced lung adenocarcinoma patients.
    Zhao, Wei
    Liu, Xingchen
    Tian, Qing
    Chang, Yan
    Yang, Zhen
    Chen, Liangan
    BIOMEDICAL RESEARCH-INDIA, 2017, 28 (04): : 1917 - 1921
  • [27] Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany
    Katharina Schremser
    Wolf H. Rogowski
    Sigrid Adler-Reichel
    Amanda L. H. Tufman
    Rudolf M. Huber
    Björn Stollenwerk
    PharmacoEconomics, 2015, 33 : 1215 - 1228
  • [28] Cost-Effectiveness of an Individualized First-Line Treatment Strategy Offering Erlotinib Based on EGFR Mutation Testing in Advanced Lung Adenocarcinoma Patients in Germany
    Schremser, Katharina
    Rogowski, Wolf H.
    Adler-Reichel, Sigrid
    Tufman, Amanda L. H.
    Huber, Rudolf M.
    Stollenwerk, Bjoern
    PHARMACOECONOMICS, 2015, 33 (11) : 1215 - 1228
  • [29] Afatinib treatment in a lung adenocarcinoma patient harboring a rare EGFR L747P mutation
    Li, Jisheng
    Zhu, Liping
    Stebbing, Justin
    Peng, Ling
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2022, 18 (05) : 1436 - 1439
  • [30] Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer
    Park, Keunchil
    Bennouna, Jaafar
    Boyer, Michael
    Hida, Toyoaki
    Hirsh, Vera
    Kato, Terufumi
    Lug, Shun
    Mok, Tony
    Nakagawa, Kazuhiko
    O'Byrne, Kenneth
    Paz-Ares, Luis
    Schuler, Martin
    Sibilotru, Denis Moro
    Tan, Eng-Huat
    Tanaka, Hiroshi
    We, Yi-Long
    Yang, James C-H
    Zhang, Li
    Zhou, Caicun
    Maerten, Angela
    Tang, Wenbo
    Yamamoto, Nobuyuki
    LUNG CANCER, 2019, 132 : 126 - 131
12345